Development of in vivo gene therapy for hearing disorders: introduction of adeno-associated virus into the cochlea of the guinea pig.
AK Lalwani, BJ Walsh, PG Reilly, N Muzyczka… - Gene therapy, 1996 - europepmc.org
AK Lalwani, BJ Walsh, PG Reilly, N Muzyczka, AN Mhatre
Gene therapy, 1996•europepmc.orgGene therapy is currently being used to treat many disorders including cancer, viral infection
and the degenerative and fatal diseases of the cardiovascular and the central nervous
systems. However, the potential use of gene therapy for alleviation of hearing impairment
has not been investigated despite the absence of effective therapy for most forms of
inherited hearing disorders. The purpose of this study was to assess the feasibility of
introducing genetic material directly into the peripheral auditory system using adeno …
and the degenerative and fatal diseases of the cardiovascular and the central nervous
systems. However, the potential use of gene therapy for alleviation of hearing impairment
has not been investigated despite the absence of effective therapy for most forms of
inherited hearing disorders. The purpose of this study was to assess the feasibility of
introducing genetic material directly into the peripheral auditory system using adeno …
Gene therapy is currently being used to treat many disorders including cancer, viral infection and the degenerative and fatal diseases of the cardiovascular and the central nervous systems. However, the potential use of gene therapy for alleviation of hearing impairment has not been investigated despite the absence of effective therapy for most forms of inherited hearing disorders. The purpose of this study was to assess the feasibility of introducing genetic material directly into the peripheral auditory system using adeno-associated virus (AAV) as the transfection vector and Hartley guinea pigs as the animal model. Approximately 10 (5) particles of AAV containing the bacterial beta-galactosidase (beta-gal) sequence with Ad 2 major late promoter were infused into the cochlea of the animal with the aid of an osmotic minipump. Animals were killed after 2 weeks. Two Hartley guinea pigs with intracochlear saline infusion and four unoperated (nonperfused) animals served as negative controls. Both, the infused and the contralateral, non-infused cochleae were harvested from each animal, decalcified, and embedded in paraffin. Sections, 8 microns in width, were cut from the embedded cochleae and assayed for beta-gal expression via immunohistochemistry. Animals perfused with AAV showed intense immunohistochemical reactivity in the spiral limbus, spiral ligament, spiral ganglion cells and the organ of Corti in the perfused cochlea and a much weaker staining but with similar pattern in the contralateral ear. Cochleae from saline-infused and unoperated animals were devoid of the DAB stain. This study demonstrates for the first time in vivo expression of a foreign gene within the mammalian inner ear resulting from its localized, AAV-mediated introduction. The ability to introduce and stably express exogenous genetic material in the peripheral auditory system will have both experimental and therapeutic benefits. These results lay the groundwork for future studies assessing the potential use of gene therapy for alleviation of hearing impairment.
europepmc.org